Tags

Type your tag names separated by a space and hit enter

Effect of isoflavones on lipids and bone turnover markers in menopausal women.
Maturitas 2004; 48(3):209-18M

Abstract

OBJECTIVES

The purpose of this analysis was to compare the effects of two dietary supplements derived from red clover to placebo on lipids and bone turnover markers in symptomatic menopausal women.

METHODS

The study was a 12-week randomized, double-blind, placebo-controlled trial. Two hundred and fifty-two menopausal women ages 45-60 years experiencing > or =35 hot flashes per week were randomly assigned to Promensil (82 mg total isoflavones), Rimostil (57.2 mg total isoflavones), or placebo. Primary outcome measures were mean absolute changes for HDL-cholesterol, serum osteocalcin, and urinary N-telopeptide. Secondary outcome measures were mean changes of total cholesterol, LDL-cholesterol, the ratio of HDL- to LDL-cholesterol, and triglycerides.

RESULTS

Ninety-eight percent of participants completed the 12-week protocol. Women taking Rimostil or Promensil compared to those taking placebo had greater mean increases in HDL-cholesterol; however, this change was small in magnitude (<2 mg/dl) and did not reach significance. There was a significant decrease in triglyceride levels among women taking Rimostil (14.4 mg/dl, P = 0.02) or Promensil (10.9 mg/dl, P = 0.05) compared to those taking placebo. The decrease was primarily among women with elevated baseline triglyceride levels (P for interaction = 0.009). There were no differences in mean changes of total cholesterol, LDL-cholesterol, or the ratio of HDL- to LDL-cholesterol among treatment groups. There were no statistically significant differences among treatment groups for bone turnover markers.

CONCLUSIONS

Compared with placebo, both of the supplements containing isoflavones decrease levels of triglycerides in symptomatic menopausal women; however, this effect is small in magnitude.

Authors+Show Affiliations

Center for Chronic Disease Outcomes Research, Minneapolis VA Medical Center, MN 55417, USA. tamara.schult@med.va.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15207886

Citation

Schult, Tamara M Knudson, et al. "Effect of Isoflavones On Lipids and Bone Turnover Markers in Menopausal Women." Maturitas, vol. 48, no. 3, 2004, pp. 209-18.
Schult TM, Ensrud KE, Blackwell T, et al. Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas. 2004;48(3):209-18.
Schult, T. M., Ensrud, K. E., Blackwell, T., Ettinger, B., Wallace, R., & Tice, J. A. (2004). Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas, 48(3), pp. 209-18.
Schult TM, et al. Effect of Isoflavones On Lipids and Bone Turnover Markers in Menopausal Women. Maturitas. 2004 Jul 15;48(3):209-18. PubMed PMID: 15207886.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of isoflavones on lipids and bone turnover markers in menopausal women. AU - Schult,Tamara M Knudson, AU - Ensrud,Kristine E, AU - Blackwell,Terri, AU - Ettinger,Bruce, AU - Wallace,Robert, AU - Tice,Jeffrey A, PY - 2003/04/08/received PY - 2003/08/01/revised PY - 2003/09/07/accepted PY - 2004/6/23/pubmed PY - 2005/3/16/medline PY - 2004/6/23/entrez SP - 209 EP - 18 JF - Maturitas JO - Maturitas VL - 48 IS - 3 N2 - OBJECTIVES: The purpose of this analysis was to compare the effects of two dietary supplements derived from red clover to placebo on lipids and bone turnover markers in symptomatic menopausal women. METHODS: The study was a 12-week randomized, double-blind, placebo-controlled trial. Two hundred and fifty-two menopausal women ages 45-60 years experiencing > or =35 hot flashes per week were randomly assigned to Promensil (82 mg total isoflavones), Rimostil (57.2 mg total isoflavones), or placebo. Primary outcome measures were mean absolute changes for HDL-cholesterol, serum osteocalcin, and urinary N-telopeptide. Secondary outcome measures were mean changes of total cholesterol, LDL-cholesterol, the ratio of HDL- to LDL-cholesterol, and triglycerides. RESULTS: Ninety-eight percent of participants completed the 12-week protocol. Women taking Rimostil or Promensil compared to those taking placebo had greater mean increases in HDL-cholesterol; however, this change was small in magnitude (<2 mg/dl) and did not reach significance. There was a significant decrease in triglyceride levels among women taking Rimostil (14.4 mg/dl, P = 0.02) or Promensil (10.9 mg/dl, P = 0.05) compared to those taking placebo. The decrease was primarily among women with elevated baseline triglyceride levels (P for interaction = 0.009). There were no differences in mean changes of total cholesterol, LDL-cholesterol, or the ratio of HDL- to LDL-cholesterol among treatment groups. There were no statistically significant differences among treatment groups for bone turnover markers. CONCLUSIONS: Compared with placebo, both of the supplements containing isoflavones decrease levels of triglycerides in symptomatic menopausal women; however, this effect is small in magnitude. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/15207886/Effect_of_isoflavones_on_lipids_and_bone_turnover_markers_in_menopausal_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378512203003578 DB - PRIME DP - Unbound Medicine ER -